Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: A possible explanation of reduced morbidity and mortality?

Critical Care Medicine

Volumn 33, Issue 3, 2005, Pages 504-510

  Siroen, Michiel P C ^a   Van Leeuwen, Paul A M ^a   Nijveldt, Robert J ^a   Teerlink, Tom ^a   Wouters, Pieter J ^b   Van Den Berghe, Greet ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; HYPERTENSIVE FACTOR; INOTROPIC AGENT; INSULIN; MONOCOMPONENT INSULIN; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; ARTICLE; ASSISTED VENTILATION; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG EFFECT; ENTERIC FEEDING; ERYTHROCYTE TRANSFUSION; ESOPHAGUS SURGERY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG SURGERY; MALE; MORBIDITY; MORTALITY; POLYNEUROPATHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SURVIVAL; TEACHING HOSPITAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ARGININE; CRITICAL ILLNESS; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; MORBIDITY; NITRIC OXIDE SYNTHASE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL RATE;

EID: 14944373609     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000155784.59297.50     Document Type: Article

References (36)

1. Gore DC, Chinkes D, Heggers J, et al: Association of hyperglycemia with increased mortality after severe burn injury. J Trauma 2001; 51:540-544
2. O'Neill PA, Davies I, Fullerton KJ, et al: Stress hormone and blood glucose response following acute stroke in the elderly. Stroke 1991; 22:842-847
3. Fietsam R, Bassett J, Glover JL: Complications of coronary artery surgery in diabetic patients. Am Surg 1991; 57:551-557
4. Van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359-1367
5. Williams SB, Cusco JA, Roddy MA, et al: Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27:567-574
6. Steinberg HO, Chaker H, Learning R, et al: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97:2601-2610
7. Chan NN, Vallance P, Colhoun HM: Nitric oxide and vascular responses in Type I diabetes. Diabetologia 2000; 43:137-147
8. Vallance P, Leone A, Calver A, et al: Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20(suppl 12): S60-S62
9. + carrier hCAT-2B. Nitric Oxide 1997; 1:65-73
10. Kakimoto Y, Akazawa S: Isolation and identification of N-G, N-G- and N-G, N′-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem 1970; 245:5751-5758
11. Kimoto M, Tsuji H, Ogawa T, et al: Detection of NG, NG-dimethylarginine dimethylaminohydrolase in the nitric oxide-generating systems of rats using monoclonal antibody. Arch Biochem Biophys 1993; 300:657-662
12. Kimoto M, Whitley GS, Tsuji H, et al: Detection of NG, NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem 1995; 117:237-238
13. Dayoub H, Achan V, Adimoolam S, et al: Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis. Genetic and physiological evidence. Circulation 2003; 108:3042-3047
14. Ito A, Tsao PS, Adimoolam S, et al: Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99:3092-3095
15. Das UN: Current advances in sepsis and septic shock with particular emphasis on the role of insulin. Med Sci Monit 2003; 9:RA181-RA192
16. Lin KY, Ito A, Asagami T, et al: Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106:987-992
17. Nijveldt RJ, Teerlink T, van der Hoven B, et al: Asymmetrical dimethylarginine (ADMA) in critically ill patients: High plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22:23-30
18. Van den Berghe G, Wouters PJ, Bouillon R, et al: Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 2003; 31:359-366
19. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
20. Miranda DR, de Rijk A, Schaufeli W: Simplified Therapeutic Intervention Scoring System: The TISS-28 items. Results from a multicenter study. Crit Care Med 1996; 24:64-73
21. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
22. Moreno R, Vincent JL, Matos R, et al: The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working group on sepsis related problems of the ES-ICM. Intensive Care Med 1999; 25:686-696
23. Teerlink T, Nijveldt RJ, de Jong S, et al: Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002; 303:131-137
24. Stühlinger MC, Abbasi F, Chu JW, et al: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287:1420-1426
25. Nijveldt RJ, Teerlink T, van Leeuwen PA: The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin Nutr 2003; 22:99-104
26. López A, Lorente JA, Steingrub J, et al: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30
27. Avontuur JA, Bruining HA, Ince C: Inhibition of nitric oxide synthesis causes myocardial ischemia in endotoxemic rats. Circ Res 1995; 76:418-425
28. Achan V, Broadhead M, Malaki M, et al: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23:1455-1459
29. Laussmann T, Janosi RA, Fingas CD, et al: Myocardial proteome analysis reveals reduced NOS inhibition and enhanced glycolytic capacity in areas of low local blood flow. FASEB J 2002; 16:628-630
30. Mann GE, Yudilevich DL, Sobrevia L: Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 2003; 83:183-252
31. +/CAT-2B and endothelial nitric oxide synthase in human fetal endothelial cells. J Physiol 2001;533:122P-123P
32. Nijveldt RJ, Teerlink T, Siroen MP, et al: The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003; 22:17-22
33. Siroen MP, Warlé MC, Teerlink T, et al: The transplanted liver graft is capable of clearing asymmetric dimethylarginine. Liver Transpl 2004; 10:1524-1530
34. Liu J, Hatzoglou M: Control of expression of the gene for the arginine transporter Cat-1 in rat liver cells by glucocorticoids and insulin. Amino Acids 1998; 15:321-337
35. Mesotten D, Swinnen JV, Vanderhoydonc F, et al: Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab 2004; 89:219-226
36. Hansen TK, Thiel S, Wouters PJ, et al: Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003; 88:1082-1088